Company intelligence / Profile preview
MARAbio Systems
- Ownership
- Private
- Development stage
- Phase 2
Overview
MARAbio has developed the first-ever blood test to detect maternal autoantibodies linked to a severe subtype of autism, enabling risk assessment before or shortly after birth. The company is also developing therapeutic interventions targeting these antibodies. Their diagnostic tool is expected to reach families in 2025, supported by recent Series A funding. Early clinical research shows over 90% predictive accuracy for identifying children at risk when mothers test positive for the relevant antibody cluster.[1][2][4]
- Therapeutic areas
- Neurology
- Modalities
- Diagnostic blood test (autoantibody detection)Therapeutic antibodies (in development)[1][2][7]
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on MARAbio Systems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MARAbio Systems.